Showing results (1991-2000 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|July 24, 2001
Cost considerations in the use of anaesthetic drugsI Smith
Pharmacoeconomics|November 14, 2016
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)Michael Willis, Pierre Johansen, Andreas Nilsson, et al.
Pharmacoeconomics|November 23, 2016
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic ReviewXinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, et al.
Pharmacoeconomics|May 9, 2014
Economic evaluations of gastroesophageal reflux disease medical managementAndrew J Gawron, Dustin D French, John E Pandolfino, et al.
Pharmacoeconomics|November 1, 2016
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness AnalysisErik Landfeldt, Lars Alfredsson, Volker Straub, et al.
Pharmacoeconomics|April 5, 2017
Discrete Choice Experiments: A Guide to Model Specification, Estimation and SoftwareEmily Lancsar, Denzil G Fiebig, Arne Risa Hole
Pharmacoeconomics|March 13, 2017
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics|March 26, 2017
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPhilip Morgan, Nerys Woolacott, Mousumi Biswas, et al.
Pharmacoeconomics|March 26, 2017
Using Parameter Constraints to Choose State Structures in Cost-Effectiveness ModellingHoward Thom, Chris Jackson, Nicky Welton, et al.
Pharmacoeconomics|March 28, 2014
Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?Klazien Matter-Walstra, Dirk Klingbiel, Thomas Szucs, et al.
Pageof 336